Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Company | Zynerba Pharmaceuticals, Inc. |
Sector | Healthcare |
Industry | Drug Manufacturers—Specialty & Generic |
Phone | 484 581 7505 |
Website | https://www.zynerba.com |
Zynerba Pharmaceuticals, Inc.ZYNE
$1.41
Administrators: admin
Top Posters:
Meredith_Editor: 84
Mike Smith: 1
Newest Members:
Erna Saunders
Jens Macarthur
dogecoinwap352 dogecoinwap352
Alexovm Alexovm
Ivanmwt Ivanmwt
Meredith_Editor
Daniel Decamp
Daniel DeCamp
Mike Smith
Daniel Decamp
Forum Stats:
Groups: 1
Forums: 85
Topics: 85
Posts: 85
Member Stats:
Guest Posters: 0
Members: 10
Moderators: 0
Admins: 1
Most Users Ever Online
21
21
Currently Online
Guest(s)
2
2
Currently Browsing this Page
1 Guest(s)
1 Guest(s)
© Simple:Press —